Bleomycin Sulfate

製品コードS1214 別名:NSC125066

Bleomycin Sulfate化学構造

分子量(MW):1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別)  
JPY 28220.00
JPY 111220.00

質量管理及び製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r2PFDjiJNzMECwJO69dQ>? MknDNlQhcMLi M{T4VolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NWXoeJM4OjZyOEi3NVE>
POLK WT MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFzLkhihKnDueLCiUGuO:Kh|ryP NF;m[IMzPjB|MUSwNC=>
POLK KO NFTJeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTRwMERihKnDueLCiUGuPVLDqM7:TR?= MnzVNlYxOzF2MEC=
POLK CD MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjFSZoxUUN3ME21MlU66oDLwsJihKkyNjBywrFOwG0> M{W1W|I3ODNzNECw
RLE/Abca3 MV7GeY5kfGmxbjDBd5NigQ>? NI\ZRncxNjUEoN88US=> MnzZNVQ1yqCq MljlbY5lfWOnczDhJI1wenCqb3zv[4lk[WxiY3jhcodmKG[{b32g[ZBqfGinbHnhcE1tcWunIH3vdpBpd2yxZ4mgeI8h[SC5aXTlMEB{eHKnYXStc5V1KG2xcoDoc4xw\3oEoB?= NIfFPHQzPTd4MEWzPC=>
PMCs NEPLN|FHfW6ldHnvckBCe3OjeR?= MojjNE4y6oDVMtMg{txoN22u NVHUdnN1OjUEoHi= MXHjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnPy[YF{\SCrbjD0bIUheHKxdHXpckBt\X[nbDDv[kBkd2yuYXflck1KyqB? M4rQSlI2PTl3NkSy
PMCs NH;aNVdHfW6ldHnvckBCe3OjeR?= MlHxNE4zyqEQvHevcYw> MXOyOQKBmzd{wrDo M{\WOIlv\HWlZYOgbY5kemWjc3XzJIlvKH[rbXXueIlvKGGwZDFOtU1UVUFicILveIVqdg>? NI\G[nMzPTV7NU[0Ni=>
PMCs NWn5T2Q1TnWwY4Tpc44hSXO|YYm= MoX5NE4zyqEQvHevcYw> NFjnNIk4OiCq MlvQbY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv M4TuZlI2PTl3NkSy
PMCs M{XLVWZ2dmO2aX;uJGF{e2G7 NGjyN2MxNjMEoN88[{9udA>? MmmwNVIwOjRxNEigbC=> MYXpcoNz\WG|ZYOgZ4VtdCCvaXfyZZRqd25? NHvrW3UzPTV7NU[0Ni=>
IMR-32 NY\tUIJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2zO{426ojUMUKwJOK2\y:vbB?= M3qxbVEz6ojUNEigbC=> NV3EcZBUUUN3ME22NEDDvWdxbXygZZQhfGinIHXu[EBw\iB{NDDodpMhd2ZiaX7jeYJifGmxbh?= MX2yOVU{PjN2NR?=
HT1080 NUC4ZlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLxNUDPxE1? MX2yOEBpyqB? NUWyPFNFdGWjZIOgeI8h[SCJMj;NJIRmdGG7 M4LmflI2PTF6OU[x
HT1080 MkXVSpVv[3Srb36gRZN{[Xl? M1[zWVEh|ryP NX3yenlIOjRiaNMg MVnpcoR2[2W|IHGgdI91\W62IHfsc4JidCCGTlGg[IFu[WenIILld5BwdnOn MVKyOVUyQDl4MR?=
HDFn MVvDfZRwfG:6aXPpeJkhSXO|YYm= NULNUXhwPzJiaB?= MUDJR|UxRTlwM{GlxsA> NYHSe5hTOjV{N{[3PVI>
THP-1 MX7DfZRwfG:6aXPpeJkhSXO|YYm= M2XaWlczKGh? NIPCe|dKSzVyPUSuO|cm M1LycFI2Ojd4N{my
HT-29 NIGw[ZhEgXSxdH;4bYNqfHliQYPzZZk> M3u5fFczKGh? NHvOd3dKSzVyPUGxMlQ6LQ>? Ml3YNlUzPzZ5OUK=
HCT116  NHjKfVREgXSxdH;4bYNqfHliQYPzZZk> NGrYSVk4OiCq M4Xr[mlEPTB;MUGuN|Qm NGDSWYgzPTJ5Nke5Ni=>
A431 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f4XVUxNTJyMDDJWS=> NWnDNJQzPDkkgJno NIS4e4NqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MlvSNlUyODF{OUm=
T24 NV;3eFFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfLXnNmPTBvMkCwJGlW M2rTelQ56oDLaB?= M2nPSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MUmyOVExOTJ7OR?=
AY-27  NI[0SGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L4d|UxNTJyMDDJWS=> NUPBelA{PDkkgJno Mo[ybY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NX\mUJdOOjVzMEGyPVk>
A549 MVTGeY5kfGmxbjDBd5NigQ>? NHvQSXEyKML3Zz;tUOKh MYewMVQ5KGh? M2XCZYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C MV6yOFk3OzZ|NR?=
MLE12 M2PTO2Z2dmO2aX;uJGF{e2G7 NIizV2UyKML3Zz;tUOKh M1:3XFAuPDhiaB?= M2rBT4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C M4LHSFI1QTZ|NkO1
Jurkat NYO3NHFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[yNQKBkc7:bR?= NHWyUFgzPOLCiXlCpC=> Mk\lZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> MoO5NlQ6OTZ6OUO=
HeLa  NIe1WWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1uxTGlEPTB;MUCuNuKh|ryP M2rSOVI1PzN{M{m3
C18-4 NXP1NodmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\QN|AuOTByIN88US=> M{m1UIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NI\HfY4zPDV5MUm4Ni=>
BMG-1  NXnCPJJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3lOFAwQDEEoN88[{9u NYPHXm1tO8LiaB?= MYDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M4rZSVI{QTB4N{K2
A459 Ml;2RZBweHSxc3nzJGF{e2G7 Ml7XNVAhdVV? MkPsOFghcA>? MVfpcoR2[2W|IHHwc5B1d3Orcx?= MlHnNlM6ODJ5Nk[=
MOCK Mnf1RZBweHSxc3nzJGF{e2G7 MVuxNEBuXQ>? NIi2dJI1QCCq NHntdZVqdmS3Y3XzJIFxd3C2b4Ppdy=> NGHLTYczOzlyMke2Oi=>
MMP1 NEXBOXBCeG:ydH;zbZMhSXO|YYm= MkG3NVAhdVV? MYS0PEBp MnfzbY5lfWOnczDhdI9xfG:|aYO= MnXxNlM6ODJ5Nk[=
A549 NUTPNW8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSyNFAh|ryP NXjWUVk1OjRiaNMg MnrD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MmHrNlM5ODV5OUO=
HCT-116 MWnBdI9xfG:|aYOgRZN{[Xl? NETsSFc{NzdwNT:xOUDPxGdxbXy= NUnWSmdRPDhiaB?= Ml\ldoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> MlLLNlM4ODh4Nki=
HeLa NYGzfWdqSXCxcITvd4l{KEG|c3H5 MW[zM|cvPS9zNTFOwIcwdWx? NWr0fnU3PDhiaB?= MnrDdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NFfGNmwzOzdyOE[2PC=>
HCT116 NYTMdop1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLPNE0yODBizsznM41t M4G1WVQ5KGh? MYjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MXOyN|UyQDJyMR?=
NCM460 NYPnfYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS5OZlUOC1zMECg{txoN22u NVjFbpB5PDhiaB?= NXn6c2NTcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MVmyN|UyQDJyMR?=
NT2  MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSyOEBpyqB? M{TJW2xFPTB;NECw5qCKyrWpL33s MViyN|M5PjR{MB?=
NT2  NX3O[IQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO0PEBp MWHMSFUxRTFyMDFCuYcwdWx? MWCyN|M5PjR{MB?=
NT2  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HCVVczKGh? MkPCUGQ2OD1{MPMAjeK2\y:vbB?= MUeyN|M5PjR{MB?=
NT2  MWnBdI9xfG:|aYOgRZN{[Xl? M2i3b|QxOOLCidM1[{9udA>? NFHhc3czPCCqwrC= NYHpeYhtcW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi NUnhWJBROjN|OE[0NlA>
NTera-2 NIHmd2tHfW6ldHnvckBCe3OjeR?= NXK4fWpnOTJyIN88[{9udA>? MnK3O|IhcA>? NI\NcFd{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> NV;MW|VXOjJ6MkWzOVU>
NCCIT MoLDSpVv[3Srb36gRZN{[Xl? M33udVEzOCEQvHevcYw> Mm\NO|IhcA>? NIHDZoN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> NWewVXZCOjJ6MkWzOVU>
NTera-2 M1TDOGZ2dmO2aX;uJGF{e2G7 MVuxNlAh|rypL33s NWf3d4lsPzJiaB?= MlTWd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz M{GzZlIzQDJ3M{W1
NCCIT MkDoSpVv[3Srb36gRZN{[Xl? Ml\2NVIxKM7:Zz;tcC=> MnzRO|IhcA>? MkH3d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz MnX6NlI5OjV|NUW=
NCCIT NX\Qe2RNTnWwY4Tpc44hSXO|YYm= MnTQNVIxKM7:Zz;tcC=> MUi3NkBp NV\pPVJOe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgS3NJKGyndnXsdy=> M13Vb|IzQDJ3M{W1
NTera-2 NIjnVnZHfW6ldHnvckBCe3OjeR?= NFHBbZEyOjBizsznM41t MV63NkBp MUHzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> MUOyNlgzPTN3NR?=
NCCIT MX;GeY5kfGmxbjDBd5NigQ>? MX:xNlAh|rypL33s M1ntWFczKGh? MmjUd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> M2LBelIzQDJ3M{W1
NTera-2 M3zJ[WZ2dmO2aX;uJGF{e2G7 MXGxNlAh|rypL33s MojBO|IhcA>? M{\jZpNq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= NYfaV3FyOjJ6MkWzOVU>
NCCIT Mn;xSpVv[3Srb36gRZN{[Xl? NYTieHZbOTJyIN88[{9udA>? MVy3NkBp MYfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy| M1jn[|IzQDJ3M{W1
MDA-MB-468 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPz[mZZOOLCk{KwNOKh|rypL33M M1u5T|I1KGh? NFX4PVlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmrUNlI5OTlzOU[=
231-H2N MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\VUpN7OOLCk{KwNOKh|rypL33M NFvMd3YzPCCq NE\pdVVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NYTUdJJGOjJ6MUmxPVY>
A549  NWfCXWVqTnWwY4Tpc44hSXO|YYm= NXHBVlFtOjByL{SwNEDPxE1? MWDy[ZN2dHS|IHnuJIEh\G:|ZT3y[ZNxd26|aY\lJIlv[3KnYYPlJIlvKFKRUx?= NW\RfWFUOjJ5N{O2PVc>
A549  MWrGeY5kfGmxbjDBd5NigQ>? MXKwMVQxOCEQvF2= NVfLWYdlOi12ODDo NUW0XYRT[2G3c3XzJI1wemVibYTEUmEhfGijbjDuSG5CKGSjbXHn[S=> MoPTNlI4PzN4OUe=
A549  MkDKSpVv[3Srb36gRZN{[Xl? M3PaSVExOCEQvF5CpC=> NWH3bYZuOOLCk{S4JIg> MoDQZ4F2e2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u NVfFWmUxOjJ5N{O2PVc>
A549  M2jPWGZ2dmO2aX;uJGF{e2G7 M3y0e|ExOCEQvF5CpC=> NGXZXYox6oDVNEigbC=> M3TwNINifXOnczDQT2QyKGOuZXH2ZYdm M2jrXFIzPzd|Nkm3
A549  NYiyXpZzTnWwY4Tpc44hSXO|YYm= M3jXc|ExOCEQvF5CpC=> NH2wdFMx6oDVNEigbC=> NIDGeldk[XW|ZYOgcYl1d2Oqb37kdolidCCub3PhcIl7[XSrb36gc4YhSmG6 MV6yNlc4OzZ7Nx?=
A549  MXnGeY5kfGmxbjDBd5NigQ>? NELqcHEyODBizszNxsA> NGi0W3Ax6oDVNEigbC=> MWrk[YNz\WG|ZYOgUW1RKGGwZDDBWHAhdGW4ZXzz NEnYTmQzOjd5M{[5Oy=>
MCF-7/Her-18  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkezNE41Oi1zN{CwJO69\y:vTB?= MmqwNlQhcA>? M2XPS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MUeyNlYzOTRyNB?=
MCF-7 MUTQSHQwWEOLIGTy[YF1dWWwdB?= Mo\lNE4zPSEQvHevcYwv MlTLNU01KGh? MUXzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 MoLjNlI2QTF{OES=
MDA-MB-231 M1;ldnBFXC:SQ1mgWJJm[XSvZX70 NYn5dnhOOC5{NTFOwIcwdWxw MX[xMVQhcA>? Ml;Ed4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> M4nOU|IzPTlzMki0
MDA-MB-235  MnjuVGRVN1CFSTDUdoVifG2nboS= M2\2bFAvOjVizsznM41tNg>? MX6xMVQhcA>? MnTGd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MnP1NlI2QTF{OES=
MCF-7 NHHjfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzLT3FwOC1{IN88[{9udC5? MYGyOE81QCCq MonISWM2OD1zLkKg{txoN22O NVnWWJoxOjJ3OUGyPFQ>
NCCIT  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXyUHUzOOLCk{G0NOKh|rypL33s MWm3NkBp NGjEfIRNTDVyPUGyNOKh|rypL33sxsA> M4K2eFIzPTZ{MU[w
NCCIT  Ml\FSpVv[3Srb36gRZN{[Xl? NHHNOlY4OiCq Monzd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= NYm1fmd{OjJ3NkKxOlA>
NCCIT  MkjtSpVv[3Srb36gRZN{[Xl? NHmyS3M4OiCq NHSxUGR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> MWmyNlU3OjF4MB?=
NCCIT  NGPGPWZHfW6ldHnvckBCe3OjeR?= NF\LSWY4OiCq MXPzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTliYXP0bZZqfHoEoB?= NHzrO|MzOjV4MkG2NC=>
NCCIT  NHfNVWRHfW6ldHnvckBCe3OjeR?= M2DWbFczKGh? Mlz5d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu MVGyNlU3OjF4MB?=
NCCIT  NHHGTVNHfW6ldHnvckBCe3OjeR?= MXO3NkBp MnSyd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGJkdC1{IHPvcpRmdnR? NEjPR5ozOjV4MkG2NC=>
NCCIT  M3fYNmZ2dmO2aX;uJGF{e2G7 MmDUO|IhcA>? M1TYVZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBEgXRvYzDs[ZZmdA>? MVeyNlU3OjF4MB?=
HeLa M17GT2Z2dmO2aX;uJGF{e2G7 NY\LV|lVOzBxN{Cg{txoN22u NUnFe4JROjUEoHi= NV:1co5QcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? MlTxNlI1QDd7M{e=
MCF-7  M3vsV2Z2dmO2aX;uJGF{e2G7 MoHsN|AwPzBizsznM41t M{TW[lI1yqCq NHKwUXFqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? MYeyNlQ5Pzl|Nx?=
HeLa MUjDfZRwfG:6aXPpeJkhSXO|YYm= NX3sdZhvOzBxN{Cg{txoN22u NIjDSnIzPMLiaB?= MmrabY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv NEjkV3czOjR6N{mzOy=>
MCF-7  M2\KVGN6fG:2b4jpZ4l1gSCDc4PhfS=> M1fLR|MxNzdyIN88[{9udA>? NFj4RYkzPMLiaB?= NIXKZlRqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= MXKyNlQ5Pzl|Nx?=
NT2 M{\4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnZSnEyODBvNkCwxsDPxGdxbXy= MWGyOEBp MnnITWM2OD12MECgxtVoN22u M3;Y[lIzPDZ7OUWy
NT2 NIqxZ|JHfW6ldHnvckBCe3OjeR?= NEXPRXE1ODEEoN88[{9udA>? NEH5S40zPCCq Mli5d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh M3LWWlIzPDZ7OUWy
NT2 NET1OIlHfW6ldHnvckBCe3OjeR?= NETERpc1ODEEoN88[{9udA>? NXzyU5BrOjRiaB?= NEexZYZ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDCRXghdGW4ZXy= M2G4O|IzPDZ7OUWy
NT2 MmjFSpVv[3Srb36gRZN{[Xl? NYjKbG9jPDBywrFOwIcwdWx? M2fzNFI1KGh? NFnUbpJ{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDCZ4wuOiCuZY\lcC=> MV:yNlQ3QTl3Mh?=
CHO NUfCb21DTnWwY4Tpc44hSXO|YYm= M3:y[VIvPcLizsznM41t MmrnNVghcC94IHS= M3Pkdolv\HWlZYRCpJBmenOrc4TlcoNmKG:oIHPodo9ud3OxbXWg[IFu[Wen M4PQWlIzOjNyMUm1
Jurkat NXjWd|lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfQZm0xNTFyMNMg{txoN22u NUTqZWNmOjRiaB?= MWXhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> NE\BN|gzOjJ{M{OzNi=>
Jurkat MlyzSpVv[3Srb36gRZN{[Xl? M4\NSlMxyqEQvHevcYw> M{PuVFI1KGh? NXHzSXFQcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDjfYNtcW6|IFSzMEBCKGGwZDDCNS=> M{\QfFIzOjJ|M{Oy
Jurkat MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDRN2VXOC1zMEFCpO69\y:vbB?= NUTlNlJDOjRiaB?= Mn3sbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx? M{GwOFIzOjJ|M{Oy
Jurkat NGLSRnhHfW6ldHnvckBCe3OjeR?= M4LRPFMxyqEQvHevcYw> NXrkOZZ1OjRiaB?= MVXpcoNz\WG|ZYOgeIhmKGWoZnXjeEBw\iCyeXPubYRqd26nIH;uJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNib3[gbIl{fG:wZTDINmEvYA>? NVPEVYdqOjJ{MkOzN|I>
U2OS EGFPnls MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzDSZAxNTMEoN88[{9udA>? M2LTSVI1KGh? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M3;LXFIyQDFzMEC3
U2OS KuEnls NEfaUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Ww[|AuOsLizsznM41t M4f5[VI1KGh? NFPPUY1qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NXnLTHQ4OjF6MUGwNFc>
MCF-7 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj3O|ExNTRyMDFOwG0> MkHHO|IhcA>? MX7MR|UxRTF3MT64xsDPxE1? MXWyNVcxOzJ7MR?=
MCF-7/Adr  M1SzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrLNE01ODBizszN MoPRO|IhcA>? MWDMR|UxRTV6LkZCpO69VcLi M{\J[lIyPzB|Mkmx
WI-38 Ml3ISpVv[3Srb36gRZN{[Xl? MX6wM|QxNzhy4pEJ{txoN22uwrC= NIHKR5Q{KGh? NFf0V4lqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NIjDcJIzOTV7OU[xNi=>
hBMSC NHTxT|dHfW6ldHnvckBCe3OjeR?= M{TsbFAwPDBxOEFihKnPxGdxbX|CpC=> Mmq1N{Bp Mm\DbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NYe5UpV{OjF3OUm2NVI>
NCI-H23 NHn2cVJHfW6ldHnvckBCe3OjeR?= M1;2cVAwPDBxOEFihKnPxGdxbX|CpC=> MWKzJIg> NG[wc5BqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NYDMOWYzOjF3OUm2NVI>
A-549 NVPHelc6TnWwY4Tpc44hSXO|YYm= NFezenUxNzRyL{iw5qCK|rypL33sxsA> NHrEc4k{KGh? MofFbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NXrU[5N6OjF3OUm2NVI>
PBL  MUPGeY5kfGmxbjDBd5NigQ>? NVTLTVJiOC92MD:4NQKBkc7:Zz;tcOKh MlLoN{Bp NXrpU25{cW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? MUiyNVU6QTZzMh?=
pol β −/− Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITPTWExNjJ3LUKwNOKh|rypL33s M4roXFI1yqCq Mn36[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh NUnjVWhSOjF{NUG5OFQ>
pol β +/+ NFzHXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDOVpYxNjJ3LUKwNOKh|rypL33s MU[yOOKhcA>? MkjK[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh Mny4NlEzPTF7NES=
pol β −/− NYiyO5RsTnWwY4Tpc44hSXO|YYm= NYPL[4MzOC1{LkWg{txoN22u M1fkN|IhcA>? MnPtZ4F2e2W|IFTORUBl[W2jZ3W= NY\CfWtxOjF{NUG5OFQ>
pol β +/+ M{jiW2Z2dmO2aX;uJGF{e2G7 NIDHOncxNTJwNTFOwIcwdWx? MUeyJIg> M2T0NYNifXOnczDEUmEh\GGvYXfl NUnQeGhbOjF{NUG5OFQ>
pol β −/− MYLGeY5kfGmxbjDBd5NigQ>? Ml35NE02KM7:Zz;tcC=> MoHKOFghcA>? NFnJOohk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> M2LMelIyOjVzOUS0
pol β +/+ NWfMfXFDTnWwY4Tpc44hSXO|YYm= NI\TTFMxNTVizsznM41t NFjGUWs1QCCq M4rVSINifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NV\t[mxLOjF{NUG5OFQ>
TK6  NXHhW44zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y1[VI2NTF3MDFOwIcwdWx? MVm5OkBp MnvTbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NGLJbZczOTB6MUS4Oy=>
TK6  sLUC+Apn1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnrUnVSOjVvMUWwJO69\y:vbB?= M37GSVk3KGh? MkWybY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NFryOZYzOTB6MUS4Oy=>
TK6 sAPE1+Apn1 NGLK[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PWSlI2NTF3MDFOwIcwdWx? NVjxW5JKQTZiaB?= MUPzbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? MmTsNlExQDF2OEe=
HCT116 M4PNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKyOU0yPTBizsznM41t M4PyWlk3KGh? NGXuSHBqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1;pO|IyODhzNEi3
HCT116 sLUC+Apn1 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvJSow6OjVvMUWwJO69\y:vbB?= MoT4PVYhcA>? M4fIe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MV:yNVA5OTR6Nx?=
HCT116 sAPE1+Apn1 M1flTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\xXGtNOjVvMUWwJO69\y:vbB?= NGTHcHM6PiCq Mk\4d4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 MVuyNVA5OTR6Nx?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作(参考用のみ)

細胞試験:

[4]

+ 展開
  • 細胞株: ADIPO-P2 cells
  • 濃度: 2.5 μg/mL
  • 反応時間: 30 minutes
  • 実験の流れ:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: CD-1 mice
  • 製剤: Saline
  • 投薬量: 5 mg/kg, 2 ml/kg
  • 投与方法: Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
Saline
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4

CAS No. 9041-93-4
保管
別名 NSC125066

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How about the strength of Bleomycin Sulfate(S1214) in terms of Units/mg?

  • 回答:

    Our S1214 Bleomycin Sulfate is 1500 Units/mg.

  • 質問2:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID